Top-Rated StocksTop-RatedNASDAQ:IRON Disc Medicine (IRON) Stock Price, News & Analysis $67.78 +1.92 (+2.92%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$67.75 -0.03 (-0.04%) As of 10/3/2025 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Disc Medicine Stock (NASDAQ:IRON) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Disc Medicine alerts:Sign Up Key Stats Today's Range$65.43▼$67.9250-Day Range$57.07▼$67.7852-Week Range$30.82▼$68.79Volume272,220 shsAverage Volume380,936 shsMarket Capitalization$2.36 billionP/E RatioN/ADividend YieldN/APrice Target$98.30Consensus RatingModerate Buy Company Overview Disc Medicine, Inc. (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options. The company's pipeline is anchored by lead programs targeting neuromuscular and hematological disorders. Disc Medicine's technology enables the discovery of novel modulators of pre-mRNA splicing and RNA–protein interactions, with therapeutic candidates advancing through preclinical development. These programs illustrate the company's commitment to translating fundamental insights in RNA biology into first-in-class or best-in-class therapies. Disc Medicine also explores oncology and rare disease indications through selective targeting of disease-driving RNA-binding proteins. Based in Cambridge, Massachusetts, Disc Medicine was founded in 2019 by a team of drug discovery scientists and RNA biologists. Since its inception, the company has established collaborations with academic institutions and research organizations to accelerate its discovery efforts. Disc Medicine's executive leadership and scientific advisory board bring extensive expertise in medicinal chemistry, structural biology and clinical development, positioning the company to advance its novel therapeutic candidates toward human trials.AI Generated. May Contain Errors. Read More Disc Medicine Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScoreIRON MarketRank™: Disc Medicine scored higher than 40% of companies evaluated by MarketBeat, and ranked 695th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingDisc Medicine has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 10 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialDisc Medicine has a consensus price target of $98.30, representing about 45.0% upside from its current price of $67.78.Amount of Analyst CoverageDisc Medicine has only been the subject of 4 research reports in the past 90 days.Read more about Disc Medicine's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Disc Medicine are expected to decrease in the coming year, from ($4.07) to ($5.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Disc Medicine is -15.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Disc Medicine is -15.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDisc Medicine has a P/B Ratio of 4.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Disc Medicine's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.76% of the float of Disc Medicine has been sold short.Short Interest Ratio / Days to CoverDisc Medicine has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in Disc Medicine has recently increased by 6.67%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDisc Medicine does not currently pay a dividend.Dividend GrowthDisc Medicine does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted9.76% of the float of Disc Medicine has been sold short.Short Interest Ratio / Days to CoverDisc Medicine has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in Disc Medicine has recently increased by 6.67%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Disc Medicine this week, compared to 6 articles on an average week.Search InterestOnly 2 people have searched for IRON on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat Follows1 people have added Disc Medicine to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Disc Medicine insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,465,583.00 in company stock.Percentage Held by InsidersOnly 3.64% of the stock of Disc Medicine is held by insiders.Percentage Held by Institutions83.70% of the stock of Disc Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Disc Medicine's insider trading history. Receive IRON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Disc Medicine and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IRON Stock News HeadlinesDisc Medicine Announces Submission of New Drug Application (NDA) to US FDA for Accelerated Approval of Bitopertin for Patients with Erythropoietic Protoporphyria (EPP)September 30, 2025 | globenewswire.comStocks With Rising Relative Strength: Disc MedicineSeptember 16, 2025 | msn.comURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash before 2025 ends. | StockEarnings (Ad)Disc Medicine, Inc. (IRON) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)September 10, 2025 | seekingalpha.comDisc Medicine Earns Relative Strength Rating Upgrade; Hits Key BenchmarkSeptember 4, 2025 | msn.comStocks To Watch: Disc Medicine Sees Relative Strength Rating Jump To 81August 27, 2025 | msn.comDisc Medicine (IRON) Receives a Buy from TD CowenAugust 9, 2025 | theglobeandmail.comDisc Medicine (IRON) Receives a Buy from Truist FinancialAugust 9, 2025 | theglobeandmail.comSee More Headlines IRON Stock Analysis - Frequently Asked Questions How have IRON shares performed this year? Disc Medicine's stock was trading at $63.40 at the beginning of 2025. Since then, IRON stock has increased by 6.9% and is now trading at $67.78. How were Disc Medicine's earnings last quarter? Disc Medicine, Inc. (NASDAQ:IRON) posted its quarterly earnings results on Thursday, August, 7th. The company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.17) by $0.41. How do I buy shares of Disc Medicine? Shares of IRON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Disc Medicine own? Based on aggregate information from My MarketBeat watchlists, some other companies that Disc Medicine investors own include NVIDIA (NVDA), Broadcom (AVGO), e.l.f. Beauty (ELF), Arista Networks (ANET), Builders FirstSource (BLDR), Novo Nordisk A/S (NVO) and Jabil (JBL). Company Calendar Last Earnings8/07/2025Today10/05/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IRON CIK1816736 Webwww.discmedicine.com Phone617-401-4400FaxN/AEmployees30Year Founded2017Price Target and Rating Average Price Target for Disc Medicine$98.30 High Price Target$132.00 Low Price Target$75.00 Potential Upside/Downside+45.0%Consensus RatingModerate Buy Rating Score (0-4)2.92 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($4.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$109.36 million Net MarginsN/A Pretax MarginN/A Return on Equity-26.60% Return on Assets-24.58% Debt Debt-to-Equity Ratio0.05 Current Ratio32.11 Quick Ratio32.11 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$14.85 per share Price / Book4.56Miscellaneous Outstanding Shares34,770,000Free Float33,501,000Market Cap$2.36 billion OptionableNot Optionable Beta0.80 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:IRON) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersThis soon could be the most precious company in AmericaCurrently, a brand-new, all-American factory outside San Antonio is becoming the most significant site in the ...True Market Insiders | SponsoredAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says th...Weiss Ratings | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredChina’s New Gold Play Could Make your Income SoarChina's New Gold Move Could Pay You up to $1,152/month. China just announced plans to store other nations' ...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Disc Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Disc Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.